Published in J Hepatol on January 01, 1985
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut (2011) 1.91
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
The biliary epithelium presents antigens to and activates natural killer T cells. Hepatology (2015) 1.52
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease. J Clin Invest (2003) 1.48
Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway. J Physiol (2008) 1.36
Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol (2005) 1.32
Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer (2002) 1.31
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res (2012) 1.19
Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem (2010) 1.19
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol (2008) 1.18
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res (2008) 1.18
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut (2011) 1.08
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
Regulation of purinergic signaling in biliary epithelial cells by exocytosis of SLC17A9-dependent ATP-enriched vesicles. J Biol Chem (2011) 1.05
Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int J Cancer (2009) 1.04
Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation. Am J Pathol (2009) 1.04
A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res (2010) 1.02
The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol (2001) 1.02
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
Altered regulation of Prox1-gene-expression in liver tumors. BMC Cancer (2008) 1.01
Leptin enhances cholangiocarcinoma cell growth. Cancer Res (2008) 1.00
Extracellular nucleotides stimulate Cl- currents in biliary epithelia through receptor-mediated IP3 and Ca2+ release. Am J Physiol Gastrointest Liver Physiol (2008) 0.94
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2011) 0.94
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol (2003) 0.93
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol (2012) 0.92
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer (2010) 0.91
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol (2013) 0.91
Identification and functional characterization of the intermediate-conductance Ca(2+)-activated K(+) channel (IK-1) in biliary epithelium. Am J Physiol Gastrointest Liver Physiol (2009) 0.91
Cytosolic Ca2+ and protein kinase Calpha couple cellular metabolism to membrane K+ permeability in a human biliary cell line. J Clin Invest (1997) 0.90
Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer (2012) 0.89
Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol (1988) 0.89
Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochem Cell Biol (2008) 0.88
Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem (2014) 0.88
Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Exp Cell Res (2010) 0.88
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest (2010) 0.88
Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Dig Liver Dis (2011) 0.87
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol (2007) 0.87
Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver Int (2009) 0.87
Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol (2007) 0.85
Mechanosensitive Cl- secretion in biliary epithelium mediated through TMEM16A. Am J Physiol Gastrointest Liver Physiol (2012) 0.84
Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol (2006) 0.83
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol (2010) 0.83
Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget (2016) 0.82
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis. Cell Commun Signal (2015) 0.82
Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis (2008) 0.82
Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest (2012) 0.82
Establishment and characterization of rat portal myofibroblast cell lines. PLoS One (2015) 0.82
miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol (2016) 0.81
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. Am J Physiol Cell Physiol (2011) 0.81
The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget (2015) 0.81
Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology (2013) 0.81
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumour Biol (2015) 0.81
Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin Exp Metastasis (2007) 0.81
Hepcidin is an antibacterial, stress-inducible peptide of the biliary system. PLoS One (2011) 0.80
The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med (2015) 0.80
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs (2014) 0.80
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. J Gastroenterol (2014) 0.80
Establishment of a new human extrahepatic bile duct carcinoma cell line (OCUCh-LM1) and experimental liver metastatic model. Br J Cancer (1995) 0.80
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer. PLoS One (2016) 0.79
Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. J Gastroenterol (2013) 0.78
XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells. PLoS One (2014) 0.78
Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci (2015) 0.78
Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro. PLoS One (2015) 0.78
Regulation of mechanosensitive biliary epithelial transport by the epithelial Na(+) channel. Hepatology (2015) 0.77
Expression of mediators of purinergic signaling in human liver cell lines. Purinergic Signal (2014) 0.77
Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer. J Mol Biomark Diagn (2013) 0.76
Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol (2014) 0.75
Ursodeoxycholyl lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins. Exp Biol Med (Maywood) (2014) 0.75
LKB1 and Notch Pathways Interact and Control Biliary Morphogenesis. PLoS One (2015) 0.75
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. Am J Pathol (2017) 0.75
PKCα regulates TMEM16A-mediated Cl- secretion in human biliary cells. Am J Physiol Gastrointest Liver Physiol (2015) 0.75
Hepatitis C virus infection of cholangiocarcinoma cell lines. J Gen Virol (2015) 0.75
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett (2016) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet (1993) 3.39
Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet (1992) 3.33
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med (1976) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol (1987) 2.54
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A (1985) 2.49
Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol (1996) 2.42
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol (1999) 2.37
Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol (1974) 2.36
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol (1997) 2.35
Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand. Nature (1987) 2.28
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut (1999) 2.24
HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology (1991) 2.24
Molecular cloning and analysis of genes for production of K5, K7, K12, and K92 capsular polysaccharides in Escherichia coli. J Bacteriol (1986) 2.23
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Endoscopic papillary dilation (EPD) for the treatment of common bile duct stones and papillary stenosis. Endoscopy (1983) 2.05
Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med (1994) 2.01
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet (2000) 2.01
Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. I. Induction of the disease and protective effect of allogeneic liver specific proteins. Br J Exp Pathol (1974) 2.00
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol (1988) 1.98
Complement-dependent B-cell activation by cobra venom factor and other mitogens? J Exp Med (1974) 1.97
HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol (1997) 1.97
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1990) 1.83
Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology (1977) 1.82
Independent and consecutive action of the complement components C5, C6 and C7 in immune hemolysis. I. Preparation of EAC1-5 with purified guinea pig C3 and C5. Immunochemistry (1970) 1.81
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur J Immunol (1976) 1.78
A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol (1997) 1.78
Differential expression of collagen types I, III, and IV by fat-storing (Ito) cells in vitro. Gastroenterology (1992) 1.78
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer (1996) 1.76
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer (1997) 1.72
Biosynthesis of enterobacterial common antigen. J Bacteriol (1985) 1.72
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation. Eur J Immunol (1973) 1.68
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med (2000) 1.67
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Surface components of Escherichia coli that mediate resistance to the bactericidal activities of serum and phagocytes. Curr Top Microbiol Immunol (1985) 1.63
IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol (1998) 1.62
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
Expression of the Escherichia coli K5 capsular antigen: immunoelectron microscopic and biochemical studies with recombinant E. coli. J Bacteriol (1990) 1.61
SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer (1997) 1.60
LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol (1979) 1.59
Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol (1995) 1.59
Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology (1990) 1.57
Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet (1991) 1.56
Interaction of C3b, B, and D in the alternative pathway of complement activation. J Immunol (1975) 1.55
Complement and monocytes are essential for provoking glomerular injury in passive Heymann nephritis in rats. Terminal complement components are not the sole mediators of proteinuria. Lab Invest (1991) 1.55
Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis (1986) 1.54
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Functional spectrum of sinusoidal endothelial liver cells. Filtration, endocytosis, synthetic capacities and intercellular communication. J Hepatol (1992) 1.51
T cell receptor triggering induces responsiveness to interleukin 1 and interleukin 2 but does not lead to T cell proliferation. J Immunol (1986) 1.50
Cardiac troponins in serum in chronic renal failure. Clin Chem (1994) 1.49
Bypass-activation of the complement system starting with C3. I. Generation and function of an enzyme from a factor of guinea-pig serum and cobra venom. Immunology (1972) 1.47
Antibodies to cell surface ganglioside GD3 perturb inductive epithelial-mesenchymal interactions. Cell (1988) 1.47
Interactions between Mycoplasma pneumoniae and guinea pig complement. Infect Immun (1975) 1.47
In vivo and in vitro binding of IgA to the plasma membrane of hepatocytes. Scand J Immunol (1978) 1.47
Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res (1990) 1.46
A new treatment for severe malabsorption due to radiation enteritis. Lancet (1996) 1.45
Autoimmune hepatitis. N Engl J Med (1995) 1.45
[Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination]. Dtsch Med Wochenschr (1993) 1.45
DNP-antigens activate the alternate pathway of the complement system. J Immunol (1974) 1.44
Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes. J Immunol (1974) 1.44
Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation (2001) 1.44
Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet (1987) 1.43
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology (1993) 1.43
Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res (1986) 1.42
Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. Proc Natl Acad Sci U S A (1980) 1.41
No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies. Ann Rheum Dis (1997) 1.41
Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A (1999) 1.41
Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res (1984) 1.40
Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res (2001) 1.39
Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol (1975) 1.39
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer (1996) 1.39
Cloning and characterisation of an immunodominant major surface antigen of Echinococcus multilocularis. Mol Biochem Parasitol (1991) 1.38